TY - JOUR
T1 - Precision Oncology
T2 - A Global Perspective on Implementation and Policy Development
AU - Horgan, Denis
AU - Tanner, Marcel
AU - Aggarwal, Charu
AU - Thomas, David
AU - Grover, Surbhi
AU - Basel-Salmon, Lina
AU - Dienstmann, Rodrigo
AU - Tan, Tira Jing Ying
AU - Park, Woong Yang
AU - Abu Rasheed, Hadi Mohamad
AU - Siu, Lillian L.
AU - Ma, Brigette
AU - Ortiz-López, Rocío
AU - Van Den Bulcke, Marc
AU - Taucher, Silvia Castillo
AU - Ferris, Andrea
AU - Starling, Naureen
AU - Malapelle, Umberto
AU - Longshore, John
AU - Saldaña, Hugo Alberto Barrera
AU - Subbiah, Vivek
N1 - Publisher Copyright:
© 2024 American Society of Clinical Oncology.
PY - 2025/1/1
Y1 - 2025/1/1
N2 - Despite the acknowledged merits of precision oncology (PO) and its increasing global implementation, its full potential for advancing care and prevention remains unrealized. The benefits are currently accessible to only limited patient segments because of multifaceted barriers. Successful implementation hinges on various factors - scientific complexities not limited to technical, clinical, regulatory, economic, administrative, and health care policy-related challenges. From building infrastructure to the associated costs, including research and development, testing, processing, and trained personnel, a lack of alignment persists. Administrative alignment with regulatory and payor acceptance is crucial. Health care policy must adapt to the ongoing shift from a one-size-fits-all treatment to a personalized approach. Without official endorsement of long-term gains over short-term costs and the health establishment's readiness for innovation, PO prospects, even in prosperous economies, may stagnate. Lower-income countries face exacerbated challenges, intensifying barriers to adoption. Nevertheless, growing awareness and utilization, driven by recognized potential for patients and public health, along with successful examples and advocacy, are progressively influencing policy for a more inclusive and beneficial approach to PO adoption.
AB - Despite the acknowledged merits of precision oncology (PO) and its increasing global implementation, its full potential for advancing care and prevention remains unrealized. The benefits are currently accessible to only limited patient segments because of multifaceted barriers. Successful implementation hinges on various factors - scientific complexities not limited to technical, clinical, regulatory, economic, administrative, and health care policy-related challenges. From building infrastructure to the associated costs, including research and development, testing, processing, and trained personnel, a lack of alignment persists. Administrative alignment with regulatory and payor acceptance is crucial. Health care policy must adapt to the ongoing shift from a one-size-fits-all treatment to a personalized approach. Without official endorsement of long-term gains over short-term costs and the health establishment's readiness for innovation, PO prospects, even in prosperous economies, may stagnate. Lower-income countries face exacerbated challenges, intensifying barriers to adoption. Nevertheless, growing awareness and utilization, driven by recognized potential for patients and public health, along with successful examples and advocacy, are progressively influencing policy for a more inclusive and beneficial approach to PO adoption.
UR - https://www.scopus.com/pages/publications/85216718058
U2 - 10.1200/GO-24-00416
DO - 10.1200/GO-24-00416
M3 - Review article
C2 - 39847746
AN - SCOPUS:85216718058
SN - 2687-8941
VL - 11
JO - JCO Global Oncology
JF - JCO Global Oncology
M1 - e2400416
ER -